Integra Lifesciences Holdings Corp
NASDAQ:IART
Intrinsic Value
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. [ Read More ]
The intrinsic value of one
IART
stock under the Base Case scenario is
63.18
USD.
Compared to the current market price of 28.68 USD,
Integra Lifesciences Holdings Corp
is
Undervalued by 55%.
Integra Lifesciences Holdings Corp's market capitalization is 2.2B USD.
IART stock price is 28.68 USD.
IART stock price (28.68 USD) is 55% less than its Intrinsic Value (63.18 USD).
IART stock price (28.68 USD) is 64% less than its Relative Value (79.56 USD). Open Relative Valuation
IART has upside potential of 58% compared to the average analyst price target.
Open Wall St Estimates
IART has positive Net Income for the last twelve months.
IART has positive three-year average ROE (Return on Equity): 10%. The company is efficient at transforming stockholders' equity into net income.
IART's Revenue has dropped by 1% over the past 12 months.
IART's ROIC (Return on Invested Capital) has decreased in the last 3 years from 8% to 7%.
IART's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
IART's Revenue has been growing by 4% per year for the last 3 years.
IART's Revenue is forecast to grow at a rate of 6% per year over the next 3 years.
IART's D/E (Debt to Equity) is very low and is equal to 0.94.
IART has positive three-year average ROIC (Return on Invested Capital): 8%. The company is efficient at using invested capital to generate operating income.
IART's ROE (Return on Equity) for the past 12 months is very low and is equal to 4%.
IART's ROE (Return on Equity) has decreased in the last 3 years from 12% to 4%.
IART has positive Operating Income for the last twelve months.
IART's long-term assets (4B USD) exceed its long-term liabilties (2B USD).
IART's Altman Z-Score is equal to 2.07.
IART has positive Free Cash Flow for the last twelve months.
IART has positive Gross Profit for the last twelve months.
IART has positive Net Debt. This means that the company has more debt (1B USD) than cash and short-term investments (309m USD).
IART generates enough operating income (272m USD) to cover interest payments on its debt (44m USD).
IART's short-term assets (1B USD) exceed its short-term liabilties (307m USD).
Valuation Backtest
Integra Lifesciences Holdings Corp
Run backtest to discover the historical profit from buying and selling
IART
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Integra Lifesciences Holdings Corp
Balance Sheet Decomposition
Integra Lifesciences Holdings Corp
| Current Assets | 1.1B |
| Cash & Short-Term Investments | 309.1m |
| Receivables | 259.3m |
| Other Current Assets | 489.6m |
| Non-Current Assets | 2.7B |
| PP&E | 496.4m |
| Intangibles | 2.1B |
| Other Non-Current Assets | 104.3m |
| Current Liabilities | 307m |
| Accounts Payable | 92.3m |
| Accrued Liabilities | 191.6m |
| Other Current Liabilities | 23.1m |
| Non-Current Liabilities | 1.9B |
| Long-Term Debt | 1.5B |
| Other Non-Current Liabilities | 402.1m |
Earnings Waterfall
Integra Lifesciences Holdings Corp
|
Revenue
|
1.5B
USD
|
|
Cost of Revenue
|
-569.1m
USD
|
|
Gross Profit
|
972.5m
USD
|
|
Operating Expenses
|
-700.7m
USD
|
|
Operating Income
|
271.8m
USD
|
|
Other Expenses
|
-204m
USD
|
|
Net Income
|
67.7m
USD
|
Free Cash Flow Analysis
Integra Lifesciences Holdings Corp
What is Free Cash Flow?
IART Profitability Score
Profitability Due Diligence
Integra Lifesciences Holdings Corp's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Integra Lifesciences Holdings Corp's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
IART Solvency Score
Solvency Due Diligence
Integra Lifesciences Holdings Corp's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Integra Lifesciences Holdings Corp's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IART Price Targets Summary
Integra Lifesciences Holdings Corp
According to Wall Street analysts, the average 1-year price target for
IART
is 45.29 USD
with a low forecast of 37.37 USD and a high forecast of 59.85 USD.
Ownership
IART Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
IART Price
Integra Lifesciences Holdings Corp
| Average Annual Return | 2.68% |
| Standard Deviation of Annual Returns | 14.24% |
| Max Drawdown | -63% |
| Market Capitalization | 2.2B USD |
| Shares Outstanding | 78 602 200 |
| Percentage of Shares Shorted | 3.08% |
Company Profile
Integra Lifesciences Holdings Corp
Country
Industry
Market Cap
Dividend Yield
Description
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. The company is headquartered in Princeton, New Jersey and currently employs 3,800 full-time employees. The firm operates through two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS segment consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield and Bactiseal. Its product offering includes CereLink in the Unites States and Europe. The Company’s TT segment focuses on three areas, which include complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment includes brands, such as Integra Dermal Matrices, AmnioExcel, SurgiMend, MicroMatrix and NeuraGen. The Company’s manufacturing and research facilities are located in California, Indiana, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, Canada, China, France, Germany, Ireland and Switzerland.
Contact
IPO
Employees
Officers
The intrinsic value of one
IART
stock under the Base Case scenario is
63.18
USD.
Compared to the current market price of 28.68 USD,
Integra Lifesciences Holdings Corp
is
Undervalued by 55%.
You don't have any saved screeners yet
